NCT00228917 - Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children | Biotech Hunter

Enrollment

798

Participants

Timeline

Start Date

June 16, 2005

Primary Completion Date

January 20, 2006

Study Completion Date

January 20, 2006

Conditions

Whole Cell PertussisTetanusHepatitis BDiphtheriaHaemophilus Influenzae Type bDiphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Interventions

BIOLOGICAL

Tritanrix-HepB/Hib-MenAC

Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine

BIOLOGICAL

Tritanrix-HepB/Hiberix

Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine

BIOLOGICAL

Mencevax-ACWY

Meningococcal Serogroups A, C, W-135 and Y Vaccine

Trial Locations (2)

1781

GSK Investigational Site, City of Muntinlupa

10400

GSK Investigational Site, Bangkok